Health Care·Biotechnology·$28.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | -22.92% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.74 | N/A | -22.92% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions impacting performance. They remain committed to their strategic goals.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite short-term setbacks.
Natera's earnings report shows a significant EPS miss, which reflects ongoing challenges in the market. Despite this, the stock rose by 2.14%, likely driven by investor optimism about future growth potential. The lack of revenue data and guidance leaves some uncertainty about the company's immediate outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Aug 4, 2025